Shein Aye Mya Sithu, Wannigama Dhammika Leshan, Hurst Cameron, Monk Peter N, Amarasiri Mohan, Badavath Vishnu Nayak, Phattharapornjaroen Phatthranit, Ditcham William Graham Fox, Ounjai Puey, Saethang Thammakorn, Chantaravisoot Naphat, Thuptimdang Wanwara, Luk-In Sirirat, Nilgate Sumanee, Rirerm Ubolrat, Tanasatitchai Chanikan, Kueakulpattana Naris, Laowansiri Matchima, Liao Tingting, Kupwiwat Rosalyn, Rojanathanes Rojrit, Ngamwongsatit Natharin, Thammahong Arsa, Ishikawa Hitoshi, Pletzer Daniel, Leelahavanichkul Asada, Ragupathi Naveen Kumar Devanga, Wapeesittipan Pattama, Ali Hosseini Rad S M, Kanjanabuch Talerngsak, Storer Robin James, Miyanaga Kazuhiko, Cui Longzhu, Hamamoto Hiroshi, Higgins Paul G, Kicic Anthony, Chatsuwan Tanittha, Hongsing Parichart, Abe Shuichi
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Center of Excellence in Antimicrobial Resistance and Stewardship Research, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Center of Excellence in Antimicrobial Resistance and Stewardship Research, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan; School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia; Biofilms and Antimicrobial Resistance Consortium of ODA receiving countries, The University of Sheffield, Sheffield, United Kingdom; Pathogen Hunter's Research Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan; Yamagata Prefectural University of Health Sciences, Kamiyanagi, Yamagata 990-2212, Japan.
Biomed Pharmacother. 2023 Oct 28;168:115793. doi: 10.1016/j.biopha.2023.115793.
Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration. Recently, adjuvants like CaEDTA have shown the ability to enhance the effectiveness of combined antimicrobial agents. Here, we tested a phage-adjuvant combination and demonstrated the effectiveness of intranasally inhaled phage (KKP10) + CaEDTA in addition to ceftazidime/avibactam (CZA) for chronic P. aeruginosa lung infections. The results emphasize that intranasal inhalation of phage along with CaEDTA can successfully re-sensitize MDR P. aeruginosa to CZA in a triple combination treatment. This promising approach shows potential as a therapy for chronic respiratory tract infections.
鉴于多重耐药（MDR）铜绿假单胞菌感染的增加，需要替代治疗方法。抗铜绿假单胞菌噬菌体疗法显示出前景，但其临床应用因耐药性的产生和缺乏生物膜穿透性而受到限制。最近，像CaEDTA这样的佐剂已显示出增强联合抗菌剂有效性的能力。在此，我们测试了噬菌体 - 佐剂组合，并证明了除头孢他啶/阿维巴坦（CZA）外，经鼻吸入噬菌体（KKP10）+ CaEDTA对慢性铜绿假单胞菌肺部感染的有效性。结果强调，在三联联合治疗中，经鼻吸入噬菌体与CaEDTA可成功使多重耐药铜绿假单胞菌对CZA重新敏感。这种有前景的方法显示出作为慢性呼吸道感染治疗方法的潜力。
Int J Antimicrob Agents. 2019-5-7
Pharmaceutics. 2025-1-15
NPJ Antimicrob Resist. 2024-10-10
Front Cell Infect Microbiol. 2024
Zotero 插件